Company Further Enhances Strength of Scientific Development & Research Team

DENVER, Dec. 15, 2010 (GLOBE NEWSWIRE) — MusclePharm(R) Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States, today announced the appointment of Michael R. Stevens, PharmD as Director of Therapeutic Nutrition.

Dr. Stevens joins MusclePharm with over twenty years of well diversified experience in the healthcare and pharmaceutical industry. In addition to his current role as Chief Strategy Officer for Virostatics, Dr. Stevens spent 17 years at Bristol-Myers Squibb, where he held positions of increasing responsibility in the areas of Market Research (Oncology and HIV), Marketing (Oncology), and Medical Affairs (HIV).

“We are extremely pleased to have Dr. Stevens join the MusclePharm team and further strengthen our position in working to add MusclePharm’s Re-con(R) and MuscleGel(R) nutritional supplements to the New York State Medicaid list of prescription medications,” commented Dr. Roscoe Moore, former United States Surgeon General, and Chief Science Director for MusclePharm. “With Dr. Stevens’ extensive experience and assistance, we plan to further MusclePharm’s support of therapeutic nutritional supplementation in the medical community.”

Nutritional Supplementation has long been utilized within the HIV community to maintain and support muscle mass and help strengthen the immune system. Whey protein has been shown through various credible studies to aid in the growth of muscle mass. Unlike other Medicaid available proteins, MusclePharm’s Re-con helps to burn fat while building muscle. This is a factor essential to people living with HIV, especially those on antiviral regimens where unwanted fat may be an issue in those who often battle muscle depletion. MusclePharm’s MuscleGel(R) represents an untapped arena of health and wellness that makes it easy to consume on the go, without the use of liquids or mixing. It’s a gel based protein supplement that enhances the body’s ability to absorb nutrients, ensures a consistent delivery of hydrated nutrients every time, providing a soothing effect to the digestive system, and tastes great.

“I am honored to join MusclePharm in their quest to provide therapeutic, nutritional supplementation,” stated Michael R. Stevens, PharmD. “MusclePharm’s Re-con Nutritional Supplement contains important amino acids, assisting in reaching the higher levels of nutrition required for people living with HIV. I will continue to contribute my diverse experiences to dynamic companies rooted in deep scientific product development and research like MusclePharm, to positively increase the delivery of their products within the medical community.”

Dr. Stevens has served as a member of the Executive Council for the Forum for Collaborative HIV Research — a public-private partnership facilitating discussion on emerging issues in HIV clinical research and working to translate research results into patient care. He has also served on 15 Protocol Committees within the Adult AIDS Clinical Trials Group (ACTG). Michael received his BS Pharmacy and Doctor of Pharmacy degrees from Purdue University.

About MusclePharm(R)

Headquartered in Denver, Colorado, MusclePharm is a rapidly expanding healthy life-style company that develops and manufactures a full line of NSF and scientifically approved, nutritional supplements that are 100% free of any banned substances. Based on years of research, MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than 100 elite professional athletes from various sports including the NFL, MMA, and MLB. The Company’s propriety and award winning products address all categories of an active lifestyle including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen. MusclePharm is sold in over 120 countries and available in over 5,000 US retail outlets that include GNC, and Vitamin Shoppe, as well as over 100 online stores, including bodybuilding.com, Amazon and Vitacost.com. For more information, please visit www.musclepharm.com.

Forward-looking Statements

MusclePharm Corporation believes the information set forth in this Press Release may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in “Risk Factors” in Item 2.02 of the Company’s Form 8-K dated February 18, 2010, which has been filed with the Securities and Exchange Commission.

Contact:

ICR
Investor Contact:
John Mills, Senior Managing Director
310.954.1105

********************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for 30 (thirty) days of advertising for MusclePharm Corporation (MSLP.OB).

DENVER, Dec. 14, 2010 (GLOBE NEWSWIRE) — MusclePharm(R) Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States, announced today that it will begin a clinical research program with the Metabolic and Body Composition Laboratory in the department of Health and Exercise Science at the University of Oklahoma to determine the effects of MusclePharm Assault(R) beginning in January 2011.

The clinical research program will be led by Jeffrey R. Stout, Ph.D, MusclePharm’s Scientific Advisor, who is an Associate Professor and Director of the OU lab. Stout, along with other faculty in the department, will study the effects of MusclePharm’s products on high-intensity interval training, on aerobic and anaerobic power, repeated sprint ability, body composition, training volume and strength levels.

MusclePharm Assault(R) is rated as a top pre-workout supplement on numerous, premier websites. Scoring 9.2 out of 10 on bodybuilding.com proves Assault(R) to be at the top of its category. With previous assessments and reviews performed by thousands of satisfied customers in conjunction with the research team at the University of Oklahoma, MusclePharm is once again proving themselves as an industry leader.

“We are excited to be working with the University of Oklahoma and such an esteemed team focused on health and exercise science to further understand the results of MusclePharm Assault(R),” commented, Brad Pyatt, MusclePharm’s Chief Executive Officer. “As one of the leading developers and manufacturers of nutritional supplements we continue to focus on safe and scientific product formulations that will benefit the global healthy living and wellness industry as we strive to increase sales and profitability long-term.”

The research team at the University of Oklahoma has conducted and published numerous studies that focus on nutritional interventions on exercise performance, muscle function and body composition, fueling excitement for MusclePharm and the future potential for the product line.

About MusclePharm

Headquartered in Denver, Colorado, MusclePharm is a rapidly expanding healthy life-style company that develops and manufacturers a full line of NSF and scientifically approved nutritional supplements that are 100% free of any banned substances. Based on years of research, MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than 100 elite professional athletes from various sports including the NFL, MMA, and MLB. The Company’s propriety and award winning products address all categories of an active lifestyle including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen. MusclePharm is sold in over 120 countries and available in over 5,000 U.S. retail outlets that include GNC, and Vitamin Shoppe, as well as over 100 online stores, including bodybuilding.com, Amazon and Vitacost.com. For more information, please visit www.musclepharm.com.

Forward-looking Statements

MusclePharm Corporation believes the information set forth in this Press Release may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in “Risk Factors” in Item 2.02 of the Company’s Form 8-K dated February 18, 2010, which has been filed with the Securities and Exchange Commission.

Contact:

ICR
Investor Contact:
John Mills, Senior Managing Director
310.954.1105

********************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for 30 (thirty) days of advertising for MusclePharm Corporation (MSLP.OB).

********************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for 30 (thirty) days of advertising for MusclePharm Corporation (MSLP.OB).

The Company Products were Chosen Based on Compliance, Results and Convenience

DENVER,December 6, 2010 (GLOBE NEWSWIRE) — MusclePharm(R) Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States, is pleased to announced that it has become an official nutritional supplement supplier for Major League’s baseball team; the Cincinnati Reds.

The partnership begins in 2011 and MusclePharm will work closely with the Cincinnati Reds and its Head Strength Coach, Matt Krause.